{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["NKT2152"]],"indication":"advanced clear cell renal cell carcinoma","name":"NKT2152-101","nct_id":"NCT05119335","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nkt2152-101-nct05119335. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Phase 1 is designed to determine the maximum tolerated dose and/or identify the recommended Phase 2 dose of NKT2152 as a single agent administered orally once daily in ccRCC patients","label":"Phase 1 dose escalation","type":"EXPERIMENTAL"},{"description":"Phase 2 dose expansion will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 as a single agent administered orally once daily in ccRCC patients. Patients will be randomized to one of two dosage levels being evaluated.","label":"Phase 2 dose expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-09-30","type":"ACTUAL"},"conditions":["ccRCC","Clear Cell Renal Cell Carcinoma","Kidney Cancer","Kidney Neoplasms","Renal Cancer","Renal Neoplasms","Recurrent Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Refractory Renal Cell Carcinoma","Advanced Renal Cell Carcinoma","Hypoxia","Renal Cell Carcinoma","Hypoxia Inducible Factor (HIF)","HIF2α Inhibitor","Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)","Hypoxia Inducible Factor 2α (HIF-2α)","Clear Cell"],"enrollment":{"count":120,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Oral NKT2152","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-12","lead_sponsor":"NiKang Therapeutics, Inc.","official_title":"Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-08-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)","timeFrame":"21 days"},{"measure":"Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)","timeFrame":"Approximately 2 years"},{"measure":"Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)","timeFrame":"Approximately 1 year"},{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"Approximately 1 year"}],"references":[],"start_date":{"date":"2021-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05119335"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nkt2152-101-nct05119335"}